CN119137152A - 抗par2抗体 - Google Patents

抗par2抗体 Download PDF

Info

Publication number
CN119137152A
CN119137152A CN202380035677.6A CN202380035677A CN119137152A CN 119137152 A CN119137152 A CN 119137152A CN 202380035677 A CN202380035677 A CN 202380035677A CN 119137152 A CN119137152 A CN 119137152A
Authority
CN
China
Prior art keywords
amino acid
seq
acid sequence
antibody
par2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380035677.6A
Other languages
English (en)
Chinese (zh)
Inventor
凯瑟琳·哈钦斯
格雷格·奥斯本
奥利弗·施伦克
克里斯托弗·奥克拉萨
安德烈·朱可夫
安妮卡·施密德
亚历山德拉·克劳斯
多雷西·鲁勒
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nexla Pharmaceuticals Uk Ltd
Original Assignee
Nexla Pharmaceuticals Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexla Pharmaceuticals Uk Ltd filed Critical Nexla Pharmaceuticals Uk Ltd
Publication of CN119137152A publication Critical patent/CN119137152A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202380035677.6A 2022-03-24 2023-03-24 抗par2抗体 Pending CN119137152A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB2204159.4A GB202204159D0 (en) 2022-03-24 2022-03-24 Antibodies
GB2204159.4 2022-03-24
PCT/GB2023/050760 WO2023180767A1 (en) 2022-03-24 2023-03-24 Anti-par2 antibodies

Publications (1)

Publication Number Publication Date
CN119137152A true CN119137152A (zh) 2024-12-13

Family

ID=81449405

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380035677.6A Pending CN119137152A (zh) 2022-03-24 2023-03-24 抗par2抗体

Country Status (10)

Country Link
US (1) US20250313621A1 (https=)
EP (1) EP4499694A1 (https=)
JP (1) JP2025510815A (https=)
KR (1) KR20240161970A (https=)
CN (1) CN119137152A (https=)
AU (1) AU2023238937A1 (https=)
CA (1) CA3246035A1 (https=)
GB (1) GB202204159D0 (https=)
IL (1) IL315704A (https=)
WO (1) WO2023180767A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024255639A1 (en) * 2023-04-14 2025-10-02 Triveni Bio, Inc. Dual inhibitor trypsin antibodies and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2327382T3 (es) 1999-07-20 2009-10-29 Morphosys Ag Metodos para presentar (poli)peptidos/proteinas en particulas de bacteriofagos a traves de enlaces disulfuro.
US7888482B2 (en) * 2006-02-10 2011-02-15 Amgen Inc. Antibodies that bind PAR-2
JO3246B1 (ar) * 2009-09-09 2018-03-08 Regeneron Pharma اجسام مضادة بشرية ذات ألفة تفاعل عالية مع مستقبل 2 المفعل بالبروتين البشري
MX2019010802A (es) 2017-03-16 2019-10-30 Medimmune Ltd Anticuerpos anti-par2 y usos de los mismos.
SMT202500106T1 (it) * 2020-08-18 2025-05-12 Cephalon Llc Anticorpi anti-par-2 e loro metodi d'uso

Also Published As

Publication number Publication date
WO2023180767A1 (en) 2023-09-28
CA3246035A1 (en) 2023-09-28
JP2025510815A (ja) 2025-04-15
US20250313621A1 (en) 2025-10-09
GB202204159D0 (en) 2022-05-11
KR20240161970A (ko) 2024-11-13
AU2023238937A1 (en) 2024-10-31
EP4499694A1 (en) 2025-02-05
IL315704A (en) 2024-11-01

Similar Documents

Publication Publication Date Title
AU2019349651B2 (en) SIRP alpha binding proteins and methods of use thereof
JP2023531989A (ja) Ｃｃｒ８抗体及びその使用
CN112566662A (zh) 针对cd47的阻断抗体及其使用方法
KR102523150B1 (ko) 항-테나신 c 항체 및 이의 용도
CN113227148B (zh) 抗gpc3抗体、其抗原结合片段及其医药用途
JP2023536631A (ja) 多重特異性結合性作用剤およびその使用
JP2024505674A (ja) 抗ｉｌ１ｒａｐ抗体
CN115298216A (zh) 抗体或其抗原结合片段、其制备方法及医药用途
US20250313621A1 (en) Anti-par2 antibodies
JP7796005B2 (ja) 抗ｔｒｅｍ－１抗体およびその使用
JP2023536629A (ja) Ｃｄ４７結合性作用剤およびその使用
JP2025503707A (ja) ガレクチン－１０抗体
WO2018077775A1 (en) Proteins and uses
JP2023536630A (ja) Ｐｄ－ｌ１結合性作用剤およびその使用
WO2021043203A1 (en) Anti-cxcr2 antibodies and uses thereof
KR20250154601A (ko) Nkg2a와 pd-l1에 결합하는 작용제 및 이의 용도
TW202540203A (zh) 結合pdgf-b與pdgf-d的抗原結合分子及使用方法
HK40107886A (zh) 抗ccr8抗体疗法：生物标志物和组合疗法
HK40110366A (zh) 半乳凝素-10抗体
HK40091263A (zh) 用於治疗应用的ccr8抗体
HK40090308A (zh) 抗ccr8抗体疗法：生物标志物和组合疗法
HK40049006B (en) Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof
HK40049006A (en) Anti-gpc3 antibody, antigen-binding fragment thereof, and medical use thereof
HK40036076B (en) Anti-trop-2 antibody, antigen binding fragment thereof and medical use thereof
HK40012331B (zh) 抗b7-h4抗体、其抗原结合片段及其医药用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination